Showing papers in "Annals of Oncology in 2009"

TL;DR: The 11th St Gallen expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers, acknowledging the role of risk factors with the caveat that risk per se is not a target.

TL;DR: Pain and pain relief should be considered integral to the diagnosis and treatment of cancer; management guidelines should be revised to improve pain control in patients with cancer.

TL;DR: XP showed significant noninferiority for PFS versus FP in the first-line treatment of AGC and can be considered an effective alternative to FP.

TL;DR: Triple-negative breast cancer is defined by a lack of expression of both estrogen and progesterone receptor as well as human epidermal growth factor receptor 2, characterized by distinct molecular, histological and clinical features including a particularly unfavorable prognosis despite increased sensitivity to standard cytotoxic chemotherapy regimens.

TL;DR: The BEAT study shows that the efficacy and safety profile of bevacizumab in routine clinical practice is consistent with results observed in prospective randomised clinical trials and another large observational study in the United States.

TL;DR: Baseline CTC count is an important prognostic factor within specific subgroups defined by treatment or patient characteristics, and unfavorable baseline CTC was associated with inferior PFS and overall survival.

TL;DR: It is confirmed that the application of preventive measures can significantly reduce the incidence of osteonecrosis of the jaw in cancer patients receiving BPs therapy and increase the number of ONJ-free patients.

TL;DR: The risk of developing Osteonecrosis of the jaw after treatment of zoledronic acid is reduced (but not deleted) by the implementation of preventive measures.

TL;DR: Patients carrying KRAS mutations or with activated PI3K profiles can benefit from targeted treatments only by switching off molecules belonging to the downstream signalling of activated EGFR, such as mammalian target of rapamycin.

TL;DR: Data is presented on the current incidence of melanoma with recent and predicted future trends illustrating a likely continuing increase in incidence and the current pattern of survival and mortality.

TL;DR: The purpose of this paper is to build on the existing knowledge and review the issues surrounding the use of chemotherapy +/- targeted agents combined with surgery in the treatment of CRC patients with liver metastases, with a view to providing clinical recommendations.

TL;DR: No clear recommendation for an antihypertensive agent can be made in this context because there is a lack of controlled studies addressing the subject.

TL;DR: Although the TNBC cells are less sensitive to EGFR inhibition than the HER-2-positive cell lines, gefitinib enhanced response to chemotherapy and combined with carboplatin and docetaxel warrants further investigation in TNBC.

TL;DR: The results show that TNBC have higher i.t. VEGF levels compared with non-TNBC, and therapy directed towards angiogenesis may be an alternative way to improve outcome in this poor prognosis group.

TL;DR: Unidimensional scales are the easiest to administer and have been most widely used and recommend the use of the EORTC QLQ C30 fatigue subscale or the FACT F, which gives a multidimensional assessment and has been widely used.

TL;DR: This prospective study demonstrates the presence of substantial discordance in receptor status between primary tumor and metastases, which led to altered management in 20% of cases.

TL;DR: Concordance of quantitative hormone receptor measurements between primary and recurrent tumors is modest consistent with suboptimal reproducibility of measurement methods, particularly for IHC.

TL;DR: The participants proposed an international consortium to facilitate further clinical and biological studies of novel EBV-driven LPDs to better define the pathogenesis, classification, and treatment of these disorders.

TL;DR: FOLFIRI in the adjuvant treatment of LMCRC showed no significant improvement in DFS compared with LV5FUs, and was compared with simplified 5-FU/FA in this setting.

TL;DR: CTC counts predict OS and provide independent prognostic information to time to disease progression to predict OS; CTC dynamics following therapy need to be evaluated as an intermediate end point of outcome in randomised phase III trials.

TL;DR: There is strong evidence that the molecular classification of breast cancer molecular subtypes is useful for clinical management and superior to World Health Organization classification in terms of short-term prognostic value.

TL;DR: The decreasing BTC mortality trends essentially reflect more widespread and earlier adoption of cholecystectomy in several countries, since gallstones are the major risk factor for BTC.

TL;DR: OS is superior in patients treated with capecitabine combinations compared with 5-FU combinations in advanced oesophago-gastric cancer.

TL;DR: BPs are an essential component of MM therapy for minimizing skeletal morbidity and a modified dosing regimen and preventive measures can greatly reduce the incidence of ONJ.

TL;DR: Cetuximab was well tolerated but had limited activity in this patient population with progressive HGG and a minority of patients may derive a more durable benefit but were not prospectively identified by EGFR gene copy number.

TL;DR: Central venous insertion modality and sites had no impact on either early or late complication rates, but US-guided subclavian insertion showed the lowest proportion of failures.

TL;DR: Cetuximab can be safely combined with CF chemotherapy and may increase the efficacy of standard CF chemotherapy.

TL;DR: Analysis of EGFR mutations in the primary lung tumor would be inadequate for planning the use of TKI for advanced NSCLC, as it does not always reflect the same situation in metastases.

TL;DR: Palliative sedation therapy does not shorten life when used to relieve refractory symptoms and does not need the doctrine of double effect to justify its use from an ethical point of view.

TL;DR: Patients undergoing sunitinib, especially those with a previous history of hypertension and coronary heart disease, are at increased risk for cardiovascular events and should be monitored for exacerbations of their hypertension and for evidence of LVEF dysfunction during treatment.